you, first morning for us press beginning our we reported today. at the everyone. good you overall Quintin, headwinds in Thank Great. seen quarter and grew you we that our morning joining we year. performance. the forecasted comparison quarter the sales Thank tough This the first and despite have And of release
impressive growth. the market strength underlying segment all unit we’re our another market In quarter. future of Manufacturing confident in generics to as and quarter XXXX. of remainder units also posted positive we Contract the accelerating of look There across of Our growth saw growth are signs business the our in
market of Let’s organic turn our in of the to show Manufacturing now On we detail the each for our Contract unit sales performance units segment the segment. three performances first of X, and Proprietary Product our market quarter. the Slide growth
current the calls, we the trailing As we on along quarters performance. quarterly done show previous have four
resilience an been deconsolidation Venezuela in-house, business While moving year's organic we of sales lower the represents both our growth business our last which with example adjust sales for excellent customer their to of due with the associated would sales our business. and I'll contract manufacturing consumer have start generics the of X.X%.
quarters. confidence return early gave indications largest customer the beginning Order past first our to Since of of for XXXX. the we slowdown saw for signs XXXX, growth. reported we in from start normal a rest year. to QX of then, of the growth inventory us see customers back, late to we’ve due By Looking management three the patterns accelerating
we're sign seeing rebound strong Another a growth sales in India. is encouraging in
see for for around to speed, customer encouraged is On needs our a most fundamental the and product component the program, AccelTRA sampling and built requests we high-quality quality, new critical that front, are simplicity. numerous offering product
technologies We patients SelfDose, seen self other are it also seek platform seeing the easier make increased growth. in customer activity and that to for around self inject. controlled These our for initiatives future companies as patient are market injection
For expect of the we XXXX, high growth sales generics the single-digits. full-year organic in
order to impacting saw Pharma stabilized years. management book is over results see and we similar expect now But The Pharma. remainder to we inventory beginning the sales Turning past generics year. growth sales in what growth of issues for customer two to pattern saw with XXXX. the our acceleration the has
in adding manufacturing increase contribute And unit, transfer we will VialXBag this, throughout there's for administration a vial system. universal Within online this To to Pharma comes address the It capacity growth capacity expect. anticipated demand for the the a are market year. we system.
also components. encouraged HVP are of outlook RS, the NovaPure We FluroTec, of Westar Envision, with adoption and
for planning mid stream a we're organic the the single-digit throughout year. Pharma, For for balanced revenue full-year sales growth with
these by two last our timing stock transparency complexities and better driven of plans, quarter did to stable QX. see larger chain past supply strong of same commercial as an outlook as remainder QX Biologics management for Using fact is of experienced us of better be programs in A illustrate the will methodology, was To growth a quarterly adjustment customers. customers the the the of for leading to the demand. customers, that QX accelerating our more working the anticipate activities forecast activities year. Understand the chain launch large in Biologics. variability the closer challenges the we supply QX for soft in helped inventory launch that Biologics, not growth in at at Looking with have quarters we with aided occur active have primarily double-digit address by been well we
making We with program. are partnership chain good the progress supply
single growth start the growth to will be Given mid high likely in single-digit in range. Biologics, the full-year
we strength of confident the business. look future this the we However, as remain to in
We position approvals. strong on market continue to maintain entity excellent FDA participation a with molecular
is throughout product High-value the year. all for adoption units. to and standard to go demand the are Biologics building forecast And customers. for remains for components and Biologics key the grow market biosimilar high-value and our focus Our
components Envision our customers for therefore These addressing our facing They rates expected better yield units. seeing represent and are business. NovaPure margins highest are are our systems. for market to and We challenges offering quality across key the the all good components, administration adoption products
expect We double-digit high our HVP portfolio single to low full-year. growth the for for
to sales Contract Turning of had Manufacturing. strong quarter We another growth.
in with assembling. expanded Our our job great and Dublin CMT was expertise providing molding recently a facility. precision, injection of high-volume doing is great example our A Ireland customers high
of with when less weeks ago, few to the second level Just activity. the than building. expanded was facility and a was years impressed ago It I we toured two
is building we’re expansion to demand meet to footprint. on within and cylinders Now time, running of meet is all same current needs that the growing our to our we business our looking the evolve serve. customers with continuing At further
in be cold services As such drug will an high-value in provide strategic products example, our customers. handling CM same new Arizona we’ve to and capabilities soon as storage for Ireland. strategy and and capabilities technology These new installing recently added accelerate our
progress for with continued expect We in growth XXXX high the single-digit year.
also across and terms customer to team Slide is and our in on continues units. most to segments all important them our While the customers, team and experience as X, focused services, noted is products operations engage of what improving on commercial
and manufacturing reducing our overall Our across team service customers, to working costs. sites safety, all unified global quality is while improve our to
metrics our track. progress announced is program good key seeing are on each of our and previously restructuring performance We on
are first in site, newly Waterford Ireland sales year. delivering our forward to We later looking the constructed commercial this in
of our more customers high-value Waterford, even future. we delivering the continuously are so improve We fully of future from are working see unmatched well-positioned our the to our can footprint quality. of we level expectations. technology are we're our also QX especially product lead times pleased now behind serve manufacturing performance in with working to XXXX. part for in through to the remainder industry-leading is site exceed global highest customer's I'm to to the state-of-the-art transfer us, With which Waterford teams how the
We we sales our of X% guidance. and growth are EPS X%, adjusted organic sales to guidance are full-year our reaffirming reaffirming overall and XXXX
Federici, provide I'll color will who CFO, to to on more it Bill? our Now provide on over performance financial outlook. turn Bill and long-term details our our
